COVID-19 Vaccine Access Uproar Underscores Importance Of At-Risk Manufacturing
Executive Summary
Sanofi CEO Hudson tries to reassure France on access, but notes that Europe does not currently have a program to assure a supply of a coronavirus vaccine as soon as safety and efficacy have been established.
You may also be interested in...
Manufacturing Pace Is Key For COVID-19 Vaccine Candidates Hoping To Jump To ‘Warp Speed’
Ease of manufacturing scale up may determine which candidates advance furthest in the US government's partnership with industry to speed COVID-19 vaccines to patients. Senior government officials also discussed approval standards, how a vaccine would be distributed, and how much the government and Americans could pay in a 16 June press call.
Trump’s ‘Warp Speed’ Initiative Could Fund 3 to 5 Large-Scale COVID Vaccine Trials
FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.
Coronavirus Update: $8bn International Fund For Vaccines Created
Plus: Eli Lilly extends its presence in COVID-19 research with an alliance with China's Junshi Biosciences.